144 related articles for article (PubMed ID: 38436699)
1. Correlation of CT parameters and PD-L1 expression status in gastric cancer.
Xu M; Ren T; Deng J; Yang J; Lu T; Xi H; Yuan L; Zhang W; Zhou J
Abdom Radiol (NY); 2024 Apr; 49(4):1320-1329. PubMed ID: 38436699
[TBL] [Abstract][Full Text] [Related]
2. Can PD-L1 expression be predicted by contrast-enhanced CT in patients with gastric adenocarcinoma? a preliminary retrospective study.
Gu X; Yu X; Shi G; Li Y; Yang L
Abdom Radiol (NY); 2023 Jan; 48(1):220-228. PubMed ID: 36271155
[TBL] [Abstract][Full Text] [Related]
3. Utility of CT radiomics for prediction of PD-L1 expression in advanced lung adenocarcinomas.
Yoon J; Suh YJ; Han K; Cho H; Lee HJ; Hur J; Choi BW
Thorac Cancer; 2020 Apr; 11(4):993-1004. PubMed ID: 32043309
[TBL] [Abstract][Full Text] [Related]
4. Correlation between imaging features on computed tomography and combined positive score of PD-L1 expression in patients with gastric cancer.
Wang Z; Wang Y; Li X; Li Y; Bu Z; Li Z; Sun Y; Ji J
Chin J Cancer Res; 2022 Oct; 34(5):510-518. PubMed ID: 36398125
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of programmed death-1, programmed death-ligand 1, programmed death-ligand 2 expression, and CD8(+) T cell density in primary tumors and metastatic lymph nodes from patients with stage T1-4N+M0 gastric adenocarcinoma.
Gao Y; Li S; Xu D; Chen S; Cai Y; Jiang W; Zhang X; Sun J; Wang K; Chang B; Wang F; Hong M
Chin J Cancer; 2017 Jul; 36(1):61. PubMed ID: 28754154
[TBL] [Abstract][Full Text] [Related]
6. Combination of clinical and spectral-CT parameters for predicting lymphovascular and perineural invasion in gastric cancer.
Ren T; Zhang W; Li S; Deng L; Xue C; Li Z; Liu S; Sun J; Zhou J
Diagn Interv Imaging; 2022 Dec; 103(12):584-593. PubMed ID: 35934616
[TBL] [Abstract][Full Text] [Related]
7. Relationship Between Programmed Death Ligand 1 Expression and Other Clinicopathological Features in a Large Cohort of Gastric Cancer Patients.
Chen X; Zhang H; Wang M; Liu H; Hu Y; Lin T; Chen H; Zhao M; Chen T; Li G; Yu J; Zhao L
Front Immunol; 2022; 13():783695. PubMed ID: 35401534
[TBL] [Abstract][Full Text] [Related]
8. [Construction of A Nomogram Prediction Model for PD-L1 Expression
in Non-small Cell Lung Cancer Based on 18F-FDG PET/CT Metabolic Parameters].
Hao L; Wang L; Zhang M; Yan J; Zhang F
Zhongguo Fei Ai Za Zhi; 2023 Nov; 26(11):833-842. PubMed ID: 38061885
[TBL] [Abstract][Full Text] [Related]
9. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
[TBL] [Abstract][Full Text] [Related]
10. Expression of Programmed Death Ligand1 (PD-L1) in Gastric Carcinoma (Histopathological and Immunohistochemical Study).
Ali SM; Helmy DO; Abdelhamid HS; Abdelmagid Mahmoud MSE
Asian Pac J Cancer Prev; 2023 Jul; 24(7):2295-2303. PubMed ID: 37505759
[TBL] [Abstract][Full Text] [Related]
11. Radiomics study for predicting the expression of PD-L1 in non-small cell lung cancer based on CT images and clinicopathologic features.
Sun Z; Hu S; Ge Y; Wang J; Duan S; Song J; Hu C; Li Y
J Xray Sci Technol; 2020; 28(3):449-459. PubMed ID: 32176676
[TBL] [Abstract][Full Text] [Related]
12.
Hu B; Chen W; Zhang Y; Shi H; Cheng D; Xiu Y
Ann Nucl Med; 2020 May; 34(5):322-328. PubMed ID: 32130663
[TBL] [Abstract][Full Text] [Related]
13. Relationship between PD-L1 expression and
Chen R; Chen Y; Huang G; Liu J
Aging (Albany NY); 2019 Dec; 11(24):12270-12277. PubMed ID: 31848322
[TBL] [Abstract][Full Text] [Related]
14. Metabolic characteristics of programmed cell death-ligand 1-expressing lung cancer on
Takada K; Toyokawa G; Okamoto T; Baba S; Kozuma Y; Matsubara T; Haratake N; Akamine T; Takamori S; Katsura M; Shoji F; Honda H; Oda Y; Maehara Y
Cancer Med; 2017 Nov; 6(11):2552-2561. PubMed ID: 28980429
[TBL] [Abstract][Full Text] [Related]
15. The Association Between Imaging Features of TSCT and the Expression of PD-L1 in Patients With Surgical Resection of Lung Adenocarcinoma.
Wu T; Zhou F; Soodeen-Lalloo AK; Yang X; Shen Y; Ding X; Shi J; Dai J; Shi J
Clin Lung Cancer; 2019 Mar; 20(2):e195-e207. PubMed ID: 30514666
[TBL] [Abstract][Full Text] [Related]
16. Scoring systems for PD-L1 expression and their prognostic impact in patients with resectable gastric cancer.
Pereira MA; Ramos MFKP; Dias AR; Ribeiro R; Cardili L; Zilberstein B; Cecconello I; Ribeiro U; de Mello ES; de Castria TB
Virchows Arch; 2021 Jun; 478(6):1039-1048. PubMed ID: 33098489
[TBL] [Abstract][Full Text] [Related]
17. Prognostic impacts of the combined positive score and the tumor proportion score for programmed death ligand-1 expression by double immunohistochemical staining in patients with advanced gastric cancer.
Yamashita K; Iwatsuki M; Harada K; Eto K; Hiyoshi Y; Ishimoto T; Nagai Y; Iwagami S; Miyamoto Y; Yoshida N; Komohara Y; Ajani JA; Baba H
Gastric Cancer; 2020 Jan; 23(1):95-104. PubMed ID: 31451991
[TBL] [Abstract][Full Text] [Related]
18. Programmed cell death protein 1/programmed death ligand 1 but not HER2 is a potential therapeutic target in gastric neuroendocrine carcinoma.
Yamashita S; Abe H; Kunita A; Yamashita H; Seto Y; Ushiku T
Histopathology; 2021 Feb; 78(3):381-391. PubMed ID: 32767778
[TBL] [Abstract][Full Text] [Related]
19. PD-L1 expression in paired biopsies and surgical specimens in gastric adenocarcinoma: A digital image analysis study.
Heo YJ; Kim B; Kim H; Kim S; Jang MS; Kim KM
Pathol Res Pract; 2021 Feb; 218():153338. PubMed ID: 33440275
[TBL] [Abstract][Full Text] [Related]
20. Standardized 18F-FDG PET/CT radiomic features provide information on PD-L1 expression status in treatment-naïve patients with non-small cell lung cancer.
Zhang R; Hohenforst-Schmidt W; Steppert C; Sziklavari Z; Schmidkonz C; Atzinger A; Kuwert T; Klink T; Sterlacci W; Hartmann A; Vieth M; Förster S
Nuklearmedizin; 2022 Oct; 61(5):385-393. PubMed ID: 35768005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
